LYON, France, Dec. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announced the launch of Ablatherm HIFU treatments at Vanderbilt University Medical Center, Nashville, TN. The treatments are part of EDAP's ongoing Phase II/III U.S. Clinical Study program seeking FDA approval as the first HIFU device for prostate cancer in the United States... EDAP's Press Release -
Tuesday, December 18, 2007
EDAP's Ablatherm HIFU treatments, Phase II/III U.S. Clinical Study program seeking FDA approval
LYON, France, Dec. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announced the launch of Ablatherm HIFU treatments at Vanderbilt University Medical Center, Nashville, TN. The treatments are part of EDAP's ongoing Phase II/III U.S. Clinical Study program seeking FDA approval as the first HIFU device for prostate cancer in the United States... EDAP's Press Release -
